文献速递肝病

遗传多态性对代谢功能障碍相关脂肪性肝病共病疾病的差异化影响

Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-04-10

这项纵向多中心队列研究纳入1178例经活检证实的代谢功能障碍相关脂肪性肝病(MASLD)患者,评估PNPLA3 rs738409、TM6SF2 rs58542926和HSD17B13 rs72613567组合对肝脏相关事件(LRE)的预测价值。遗传高风险组LRE风险比为1.91(95%CI,1.20-3.04),该关联在不伴肥胖、不伴糖尿病及较年轻患者中更强。作者认为该变异组合有助于日本MASLD患者的LRE风险评估。

要点

  • 遗传纤维化评分2、3、4或5分者LRE风险均高于0或1分者。
  • PNPLA3和TM6SF2而非HSD17B13与LRE发生显著相关。
  • 遗传高风险组LRE风险比为1.91(95%CI,1.20-3.04)。

核心结论

  • MASLD相关遗传变异组合有助于预测日本MASLD患者的肝脏相关事件(LRE)。
  • 该遗传风险有助于LRE风险评估,尤其适用于不伴代谢危险因素或较年轻的日本患者。

研究设计与样本

  • 纵向多中心队列研究,纳入1178例经活检证实的MASLD患者。
  • 根据PNPLA3 rs738409、TM6SF2 rs58542926和HSD17B13 rs72613567的影响计算遗传性肝纤维化评分和LRE遗传风险。

主要发现

  • 遗传纤维化评分2、3、4或5分者LRE风险均高于0或1分者,比值比分别为2.45(95%CI,1.27-4.74)、2.14(95%CI,1.17-3.94)和2.54(95%CI,1.35-4.77)。
  • 多因素分析显示PNPLA3和TM6SF2而非HSD17B13与LRE发生显著相关。
  • 遗传高风险组LRE风险比为1.91(95%CI,1.20-3.04)。
  • 在F≥3或Fibrosis-4指数>2.67的患者中亦可见遗传高风险组LRE风险升高。
  • 遗传高风险组LRE风险比在不伴肥胖、不伴糖尿病及较年轻患者中分别高于伴肥胖、伴糖尿病或较年长患者。

关键数值与推荐

  • 遗传纤维化评分2分者LRE比值比2.45(95%CI,1.27-4.74),参照为0或1分者。
  • 遗传纤维化评分3分者LRE比值比2.14(95%CI,1.17-3.94),参照为0或1分者。
  • 遗传纤维化评分4或5分者LRE比值比2.54(95%CI,1.35-4.77),参照为0或1分者。
  • 遗传高风险组LRE风险比1.91(95%CI,1.20-3.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 have been associated with an increased risk of liver-related events (LREs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). In this study, we investigated the combined effects of these variants on LREs. METHODS: The longitudinal multicenter cohort study enrolled 1178 patients with biopsy-proven MASLD. We calculated the genetic risk of hepatic fibrosis and LRE according to the impact of these variants. RESULTS: Patients with genetic fibrosis scores of 2, 3, and 4 or 5 were at greater risk than patients with scores of 0 or 1, with odds ratios of 2.45 (95% CI, 1.27-4.74), 2.14 (95% CI, 1.17-3.94), and 2.54 (95% CI, 1.35-4.77), respectively. Multivariate analysis revealed that PNPLA3 and TM6SF2, but not HSD17B13, were associated significantly with LRE development. The hazard ratio of the genetic high-risk group for LRE was 1.91 (95% CI, 1.20-3.04). The higher risk of LRE development in the genetic high-risk group also was seen in patients with F ≥ 3 or Fibrosis-4 index > 2.67. The hazard ratios of the genetic high-risk group for LRE were greater in patients without obesity, without diabetes, and of younger age compared with patients with obesity, with diabetes, or of older age, respectively. CONCLUSIONS: This combination of MASLD-related genetic variants is useful for predicting LREs in Japanese patients with MASLD. The genetic risk according to these variants is useful for LRE risk assessment, especially in patients without metabolic risk factors or in younger patients in Japan.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Seko Y, Yamaguchi K, Shima T, et al. Differential Effects of Genetic Polymorphism on Comorbid Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38604296. doi:10.1016/j.cgh.2024.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。